Liu Kailie of Qizheng Tibetan Medicine: Using the modernization of Tibetan medicine as the key, we can unlock the door to the era of greater health.

Between the towering snow-capped mountains and river valleys of the Qinghai-Tibet Plateau grows a wealth of natural medicinal herbs that have been revered as treasures by Tibetan medicine for thousands of years. Qizheng Tibetan Medicine, a company originating from Tibet and deeply rooted in traditional Tibetan medicine for 30 years, is steadily forging ahead amid the waves of modernization and globalization, guided by its philosophy of upholding tradition while embracing innovation.

As the only A-share listed company specializing in Tibetan medicine, Qizheng Tibetan Medicine has not only won widespread public trust with its flagship product, “Xiaotong Paste,” but has also laid out a second growth trajectory in areas such as respiratory, neurological, and gynecological diseases, demonstrating strong innovation drive and strategic foresight.

In a recent exclusive interview with a reporter from the Shanghai Securities Journal, Liu Kailie, Chairman of the company, stated: “The foundation for dialogue between traditional medicine and modern medicine is our shared goal—curing diseases and saving lives. It is precisely around this goal that we are promoting the systematic development and global promotion of Tibetan medicine.”

Rooted in Tibetan medical wisdom, we are building an integrated and innovative system.

Tibetan medicine is an important branch of traditional Chinese medicine, originating on the Qinghai-Tibet Plateau. It integrates the essence of Bon medicine, Chinese medicine, Indian Ayurveda, and Persian medicine, with the “Three Factors Theory” (Lung, Tripa, and Bkra-shis) at its theoretical core. This theory emphasizes the holistic balance between human energy and natural rhythms.

“Traditional Tibetan medicine’s understanding of human life is based on the Three Factors system: Lung represents kinetic energy, Tserba represents thermal energy, and Beken represents the material foundation. These three energies are closely linked to the circadian rhythm; balance among them signifies health, while imbalance leads to illness,” said Liu Kaili. He added that this systematic concept provides a fresh perspective for the management of modern chronic diseases, complex illnesses, and geriatric conditions, and has also become the cornerstone for Qizheng Tibetan Medicine’s product development and clinical applications.

In promoting the integration of Tibetan and Western medicine, the company has undertaken numerous clinical collaborations and research studies. For example, in the treatment of chronic pelvic inflammatory disease, Tibetan medicine intervention has reduced the recurrence rate by approximately 40% while significantly minimizing the side effects of Western medications. In the field of oncology support, “Qingpeng Ointment” effectively alleviates systemic dermatitis and eczema caused by chemotherapy in patients.

“We are facing common health challenges. The holistic approach and external treatment methods of Tibetan medicine can precisely make up for certain shortcomings of modern medicine—namely, its localized treatments and the prominent side effects associated with pharmaceuticals,” Liu Kailie explained. Currently, the company relies on over 400,000 mu of plateau cultivation bases to ensure the authenticity and consistent quality of medicinal materials right from the source. It has also established an R&D system that covers classical research, pharmacological studies, and formulation innovation, creating an integrated model driven by four key dimensions: theory, resources, technology, and clinical practice.

Our flagship products and diversified pipeline work in synergy to deliver steady growth that transcends economic cycles.

As the company’s flagship product, “Xiaotong Tie Gao” has become a leading brand in China’s musculoskeletal pain care sector. Behind its success lies Qizheng’s ongoing exploration of the modernization of Tibetan medicine.

Liu Kailie introduced that this product employs ultra-low-temperature freeze-drying technology to preserve the active ingredients of medicinal herbs. By leveraging a wet-application activation mechanism, it achieves deep-tissue pain relief and has been included in numerous national-level clinical practice guidelines. “The ‘Xiaotong Tie Gao’ is not merely a traditional topical plaster—it contains a wealth of innovative technological elements... It can maintain the activity of medicinal herbs, ensure long-term preservation, and upon application, reawaken the medicinal ingredients’ activity, allowing them to penetrate deep into the body’s tissues to provide pain relief and anti-inflammatory effects.”

It is reported that, in addition to the consumer market for personal use, this product is also widely used in medical settings, demonstrating clear clinical value.

In terms of diversified development, the company is systematically advancing the expansion of its product pipeline. In addition to its core focus on pain management, it has already established a presence in high-potential areas such as the respiratory system (e.g., chronic obstructive pulmonary disease), the nervous system (e.g., post-stroke rehabilitation), and gynecology (e.g., chronic pelvic inflammatory disease).

“We focus on patients and orient our product pipeline around clinical and health issues,” said Liu Kailie. These strategic arrangements precisely reflect the shifts in disease patterns brought about by an aging society—rising prevalence of chronic diseases and increasing demand for rehabilitation management—while also providing the company with sustained growth momentum. In recent years, the company has maintained steady performance growth, with revenue achieving double-digit increases for several consecutive years, demonstrating strong cyclical resilience and development agility.

Adhere to long-termism and move toward becoming a global health industry group.

As a leader with formal training in pharmacy, Liu Kailie’s personal journey is closely intertwined with the development trajectory of Qizheng Tibetan Medicine.

He graduated from Shanghai Medical University (now the School of Medicine at Fudan University). His original aspiration to enter the pharmaceutical industry stemmed from a profound family experience during his childhood. As the eldest son in his family, he had a younger brother born in the 1970s who unfortunately contracted hepatitis B—a disease that was not only common at the time but also meant that patients could not attend school normally. As a young boy, he often found himself taking his younger brother around to various doctors and pharmacies in search of treatment.

This experience deeply planted in his heart the seed of seeking a cure for patients. “Since childhood, I’ve often thought: If only I could find a medicine that relieves patients’ suffering, that might just be the career I’d most passionately pursue in this life.” This original aspiration not only guided him onto the path of pharmacy but also forged a profound connection between him and Tibetan medicine. “Looking back now, I feel incredibly fortunate—my current profession still closely aligns with my earliest inner desire.”

This sense of mission, rooted in life experiences, is also deeply integrated into Qizheng’s corporate strategy.

Facing the future, Liu Kailie has set forth a three-phase goal: within five years, focus on the pain relief field to double the company’s business; within ten years, build a comprehensive 10-billion-yuan Tibetan medicine industry chain; and by the thirtieth year, establish a Tibetan medicine and health industry group with international influence. Underlying this vision is the company’s sustainable development strategy framework, which encompasses five key pillars: health care, cultural heritage, technological innovation, resource conservation, and employee development.

Liu Kailie stated: “Qizheng is a mission-driven publicly listed company. Our mission is ‘to promote health and wisdom, and to create value in life.’” In his view, Tibetan medicine is not only a cultural heritage but also a medical resource that can be standardized, modernized, and国际化 (internationalized).

In terms of heritage, the company consistently adheres to classic original formulas, authentic medicinal herbs, and Tibetan medical theory. All of its products are derived from Tibetan medical texts and have undergone modern clinical validation. As for innovation, the company continues to invest in improving dosage forms, exploring pharmacological mechanisms, and conducting international registration studies. To date, several of the company’s products have been registered overseas and have entered local markets, and its international expansion is steadily advancing. Liu Kailie also expressed his confidence to investors: “Traditional Tibetan medicine is a cultural treasure of our nation. We will continue to promote its development through modernization, standardization, and internationalization, thereby creating greater value for our investors.”

Looking back at Qizheng Tibetan Medicine’s 30-year journey of development, its core secret lies in embracing innovation, respecting tradition, and seamlessly integrating with the market. Through three decades of relentless dedication, Qizheng Tibetan Medicine has not only become a benchmark for the modernization of Tibetan medicine but has also provided a replicable development model for the entire traditional medicine industry—grounded in culture yet moving toward science; rooted in local traditions yet reaching out to the world. As Liu Kailie put it: “Everything we do is aimed at helping people live longer and live better.” And perhaps this is precisely the most fundamental mission of the pharmaceutical industry.

Reporting agency: Xinhua News Agency

Report link: https://h.xinhuaxmt.com/vh512/share/12708335?docid=12708335&newstype=1001&d=13500cc&channel=weixin